Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: L-Carnitin, Nefrocarnit; Cyprus: Levocarnil, Soludamin, Trian; Czech Republic: Carnitene, L-Carnitin; France: Levocarnil; Germany: Biocarn, Carnitin, L-Carn, L-Carnit, Levocarn, Nefrocarnit; Greece: Aminocer, Aveptol, Bitobionil, Carniben, Carnidose, Carnil, Carniprol, Carnisac, Carnitop, Corubin, Duocarnic, Energocarnil, Ensial, Ergogen, Frutenor, Growart, Inestom, Intelecta, Koptilan, Lecarna, Levalastine, Levamin, Levars, Levicin, Levocarnil, Levocuor, Levosan, Lisefor, Listover, Locar, Lofostin, Lyzip, Medicardin, Merlit-Leovan, Mevamyst, Minartine, Minoa, Oskana, Phacovit, Revotonine, Ridovet, Soludamin, Superamin, Trian, Trinalin, Vigorup, Xaritic; Italy: Branigen, Cardiobil, Carnitene; Latvia: Nefrocarnit; Netherlands: Carnitene, Levocarnitine, Nefrocarnit; Poland: Carnivit; Portugal: Cartine, Disocor; Romania: Carnil, Miocor; Slovakia: L-Carnitin; Spain: Carnicor, Carnitina, Secabiol; UK: Carnitor.

North America

Canada: Carnitor; USA: Carnitor, Levocarnitine.

Latin America

Argentina: Albicar, Carnitina, L-Carnitine; Mexico: Cardispan, Lipovitasi D, Provicar.


Japan: L-Cartin.

Drug combinations


Levocarnitine: C~7~H~15~NO~3~. Mw: 161.20. (1) 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, (R)-; (2)(L-3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt. CAS-541-15-1 (1987).

Levocarnitine Propionate Hydrochloride: C~10~H~20~ClNO~4~. Mw: 253.72. (1) 1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)-; (2)(2R)-3-Carboxy-N,N,N-trimethyl-2-(propanoyloxy)propan-1-aminium chloride. CAS-119793-66-7 (2002).

Pharmacologic Category

Nutritional Supplement. (ATC-Code: A16AA01).

Mechanism of action

A naturally-occurring metabolic compound which functions as carrier molecule for long-chain fatty acids within mitochondria, facilitating energy production. Carnitine deficiency associated with accumulation of excess acyl CoA esters and disruption of intermediary metabolism.

Therapeutic use

Primary systemic carnitine deficiency. Acute and chronic treatment of inborn error of metabolism which results in secondary carnitine deficiency. Prevention and treatment of carnitine deficiency in end-stage renal disease undergoing hemodialysis.

Pregnancy and lactiation implications

Teratogenic effects not observed in animal studies. Carnitine is a naturally-occurring substance in mammalian metabolism. Use caution during lactation (potential exposure of infant to increased carnitine intake).

Unlabeled use


Warnings and precautions

Caution with compromised renal function or end-stage renal disease patients on dialysis (risk of accumulation of potentially toxic metabolites with chronic administration). Use with caution in seizure disorders.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart